Centocor's Analysis Of Remicade Medicare Costs Relies On Low Dose
A Centocor analysis comparing Medicare costs for Remicade to Immunex' Enbrel relies on an assumption that physicians would use the low dose of Remicade.
You may also be interested in...
Centocor Remicade labeling should indicate that some patients may benefit from a higher dosage of the drug, but should also emphasize the greater safety risks associated with higher dosing, members of the FDA Arthritis Drugs Advisory Committee suggested.
The estimated cost of Immunex' Novantrone for treatment of multiple sclerosis is $5,107 per year excluding the cost of cardiac monitoring, according to a Lewin Group analysis released March 14.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011